DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Proquad (Measles, Mumps, Rubella, Varicella Virus Vaccine Live) - Summary

 
 



PROQUAD SUMMARY

ProQuad [Registered trademark of Merck & Co., Inc. Copyright 2005 Merck & Co., Inc. All rights reserved] is a combined attenuated live virus vaccine containing measles, mumps, rubella, and varicella viruses.

ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

ProQuad may be used in children 12 months through 12 years of age if a second dose of measles, mumps and rubella vaccine is to be administered.


See all Proquad indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Proquad (Measles, Mumps, Rubella, Varicella Virus Vaccine Live)

Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). [2007.06]
OBJECTIVE: A refrigerator-stable formulation of ProQuad has been developed to expand the utility of ProQuad to areas in which maintenance of a frozen cold chain (-15 degrees C or colder) during storage and transport may not be feasible. The objective of this study was to demonstrate that the immunogenicity and safety profiles of a refrigerator-stable formulation of ProQuad are similar to the recently licensed frozen formulation... CONCLUSIONS: The refrigerator-stable formulation of ProQuad is generally well tolerated, highly immunogenic, and noninferior in terms of postvaccination antibody responses. This refrigerator-stable formulation may improve ease of vaccine administration, increase use of the vaccine throughout the world because of its improved storage conditions, and replace the frozen formulation of ProQuad or any dose of M-M-RII and Varivax in routine practice.

Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). [2010.05.07]
This report presents new recommendations adopted in June 2009 by CDC's Advisory Committee on Immunization Practices (ACIP) regarding use of the combination measles, mumps, rubella, and varicella vaccine (MMRV, ProQuad, Merck & Co., Inc.). MMRV vaccine was licensed in the United States in September 2005 and may be used instead of measles, mumps, rubella vaccine (MMR, M-M-RII, Merck & Co., Inc.) and varicella vaccine (VARIVAX, Merck & Co., Inc.) to implement the recommended 2-dose vaccine schedule for prevention of measles, mumps, rubella, and varicella among children aged 12 months-12 years.

Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. [2008.11]
CONCLUSION: There are insufficient published data to derive evidence-based guidelines for use of live viral vaccines in transplant recipients on immunosuppression but preliminary data on efficacy and safety suggest that the use of these live viral vaccines in transplant recipients still on immunosuppression could be a reasonable strategy.

[Priorix Tetra: a new combined vaccine against measles, rubella, mumps and varicella] [2008.08]
Varicella is an infectious disease caused by a virus of the herpes virus family (VZV) affecting predominantly the pediatric age. Varicella is considered a mild disease, but in some cases, mainly in immunocompromised subjects, it can evolve towards complicated cases, even fatal.This review summarizes the epidemiology of measles, mumps, rubella and varicella in Italy, encompassing the rationale for the introduction of varicella vaccination and describes the immunological, clinical and safety profile of Priorix Tetra.

A combination vaccine against measles, mumps, rubella and varicella. [2008.04]
A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella.

more studies >>

Clinical Trials Related to Proquad (Measles, Mumps, Rubella, Varicella Virus Vaccine Live)

ProQuad Dose Selection Study (V221-011)(COMPLETED) [Completed]

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) [Completed]
The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) [Completed]
This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study [Completed]
Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella [Oka/Merck] Virus Vaccine Live will be given concomitantly or non-concomitantly. Safety data will be collected following each vaccination.

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines [Completed]
This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.

more trials >>


Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015